pharma · Diabetes Mellitus · Hemophilia A
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Approved · small molecule · Lymphoma
Brentuximab vedotin (ADCETRIS) is an approved antineoplastic agent developed and commercialized by Takeda Pharmaceuticals for the treatment of lymphoma. The drug is administered by injection and belongs to the therapeutic class of antineoplastic and immunomodulating agents (ATC L01). As an approved therapy, brentuximab
Internal code C25006
Brentuximab vedotin (ADCETRIS) is an approved antineoplastic agent developed and commercialized by Takeda Pharmaceuticals for the treatment of lymphoma. The drug is administered by injection and belongs to the therapeutic class of antineoplastic and immunomodulating agents (ATC L01). As an approved therapy, brentuximab vedotin represents an established treatment option in the lymphoma market, with regulatory authorization across multiple major markets including the United States, European Union, Australia, and Japan. The program maintains active status with a latest milestone recorded on 19 September 2025, indicating ongoing commercial or clinical activity. Takeda's strategy centers on maintaining market presence and potentially expanding the clinical evidence base through active trials, as evidenced by ongoing registrations (NCT01909934 and NCT05673785). The drug's approval history spans multiple jurisdictions with first Australian listing in December 2014, European authorization in February 2026, and Japanese approvals documented from January 2014 onwards. Current development focus appears directed toward sustaining market position within the competitive lymphoma treatment landscape rather than pursuing novel indication expansion at this stage.
Lymphoma represents a significant oncology market with substantial unmet medical needs across both Hodgkin and non-Hodgkin subtypes. Brentuximab vedotin addresses a clinically important patient population requiring effective systemic therapy options. The drug's approval across multiple regulatory jurisdictions underscores its clinical utility and commercial relevance in treating lymphoid malignancies. Market significance is evidenced by sustained regulatory presence and active clinical trial engagement, suggesting continued clinical demand and commercial viability. The competitive landscape includes multiple approved antineoplastic agents targeting overlapping patient populations, including IMBRUVICA (Janssen-Cilag), KYPROLIS (Amgen), and various chemotherapy regimens, indicating a mature but active therapeutic category. Brentuximab vedotin's positioning within this landscape reflects its established role as a standard-of-care option for specific lymphoma subtypes. Patient population reach extends across multiple geographic markets with documented regulatory approvals, supporting broad clinical accessibility. The drug's sustained active status and recent milestone activity (September 2025) indicate ongoing commercial importance and potential for continued clinical development or label expansion initiatives. Takeda's continued investment in supporting trials suggests confidence in the program's long-term market relevance and potential for deepening clinical evidence within the lymphoma indication.
Drug Class: Antineoplastic and immunomodulating agent (ATC L01)
Modality: Small molecule
Route of Administration: Injection
Brand Name: ADCETRIS
International Nonproprietary Name (INN): Brentuximab vedotin
Mechanism of Action: Not yet disclosed in available documentation
Molecular Target: Not yet disclosed in available documentation
Related Therapies: Competing lymphoma treatments include IMBRUVICA (ibrutinib, Janssen-Cilag), KYPROLIS (carfilzomib, Amgen), VYXEOS LIPOSOMAL (daunorubicin/cytarabine, Jazz Pharmaceuticals), and conventional chemotherapy agents such as PACLITAXEL ACCORD (Accord Healthcare)
First Approval: January 2014 in Japan; December 2014 in Australia; February 2026 in European Union; approval in United States under BLA applications 125388 and 125399 (sponsor: Seattle Genetics)
Patent Status: Not yet disclosed
Also known as: lymphoma (Hodgkin and non-Hodgkin), lymphoma (Hodgkin's and non-Hodgkin's), lymphoma, malignant, lymphomatous, malignant lymphoma, MLYM
A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
ClinicalTrials.gov lists 16 registered studies for Lymphoma, Hodgkin (AACT aggregate).
Phase breakdown: NA (10), PHASE1 (3), PHASE2 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005062), Orphanet — lymphoma, NCT00026208, NCT00578461, NCT01459224, NCT02996773, NCT03117036, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Japan approval
Brentuximab vedotin approved in Japan.
Australia approval
First Australian listing on ARTG with PBS codes assigned.
Australia label expansion
Additional PBS code listing in Australia indicating potential indication or formulation expansion.
Australia further listing
Additional PBS code listing in Australia.
European Union approval
EMA authorization granted under EMEA/H/C/002455.
Latest milestone
Most recent program activity recorded; specific milestone nature not yet disclosed.
Brentuximab vedotin operates within a competitive lymphoma treatment market populated by multiple approved antineoplastic agents. Key competitors identified include IMBRUVICA (ibrutinib, Janssen-Cilag), a Bruton tyrosine kinase inhibitor approved for lymphoid malignancies; KYPROLIS (carfilzomib, Amgen), a proteasome inhibitor for multiple myeloma and lymphoma; VYXEOS LIPOSOMAL (daunorubicin/cytarabine, Jazz Pharmaceuticals), a liposomal chemotherapy combination; and AFINITOR (everolimus, Novartis), an mTOR inhibitor. Additional competitive agents include UNITUXIN (dinutuximab, United Therapeutics), a monoclonal antibody; LYNOZYFIC (anifrolumab, Regeneron), an interferon-beta receptor antagonist; and conventional chemotherapy options such as PACLITAXEL ACCORD (Accord Healthcare). Pfizer Australia maintains market presence through multiple approved agents including INLYTA (axitinib). This competitive environment reflects the substantial clinical and commercial importance of lymphoma treatment, with multiple mechanistic approaches represented. Brentuximab vedotin's sustained regulatory approvals across major markets (US, EU, Australia, Japan) and active clinical trial engagement indicate competitive viability. The diversity of competing mechanisms—ranging from tyrosine kinase inhibitors to monoclonal antibodies to conventional chemotherapy—suggests segmented market positioning based on lymphoma subtype, patient characteristics, and treatment line.
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Approved via BLA applications 125388 and 125399 (sponsor: Seattle Genetics); status confirmed as approved through FDA databases.
European Union: Approved under EMA authorization EMEA/H/C/002455 with Marketing Authorization Holder (MAH) Takeda Pharma A/S; authorization date 18 February 2026.
Australia: Approved and listed on ARTG with multiple PBS codes assigned (10166C, 10171H, 10172J, 10180T, 11067L, 11073T, 11079D, 11080E, 11086L, 11087M); sponsor Takeda Pharmaceuticals Australia Pty. Ltd.; first listing 1 December 2014 with subsequent listings in April 2017 and April 2019 indicating label or formulation expansions.
Japan: Approved with documented approval dates January 2014, September 2018, and December 2019, indicating multiple approvals or label expansions; regulatory authority PMDA.
China (NMPA): Regulatory status not yet disclosed.
Loss of Exclusivity: Expected LOE date not yet disclosed.
Brentuximab vedotin (ADCETRIS) is an approved antineoplastic agent used for the treatment of lymphoma. Specific lymphoma subtypes and treatment lines are not yet disclosed in available documentation.
Yes, brentuximab vedotin is approved in multiple major markets including the United States (BLA 125388, 125399), European Union (EMEA/H/C/002455, approved 18 February 2026), Australia (ARTG listing since 1 December 2014), and Japan (approved January 2014 and subsequent dates).
Brentuximab vedotin is developed and commercialized by Takeda Pharmaceuticals. In the United States, Seattle Genetics is listed as the original sponsor for FDA approvals.
The brand name is ADCETRIS.
Brentuximab vedotin is administered by injection.
Brentuximab vedotin belongs to the therapeutic class of antineoplastic and immunomodulating agents (ATC L01).
The specific mechanism of action is not yet disclosed in available documentation.
The specific molecular target is not yet disclosed in available documentation.
Two active trials are registered: NCT01909934 and NCT05673785. Specific trial objectives, designs, and endpoints are not yet disclosed.
Brentuximab vedotin was first approved in Japan in January 2014, followed by Australia in December 2014, and the European Union on 18 February 2026.
Competing lymphoma treatments include IMBRUVICA (Janssen-Cilag), KYPROLIS (Amgen), VYXEOS LIPOSOMAL (Jazz Pharmaceuticals), AFINITOR (Novartis), UNITUXIN (United Therapeutics), and conventional chemotherapy agents.
Regulatory status in China (NMPA) is not yet disclosed in available documentation.
Brentuximab vedotin is classified as a small molecule.
No partner is listed in current documentation; Takeda maintains full development and commercialization responsibility.
Brentuximab vedotin maintains active approved status with recent milestone activity recorded on 19 September 2025, indicating ongoing commercial or clinical engagement.
Multiple PBS code listings in Australia (2014, 2017, 2019) suggest prior label or formulation expansions; future expansion plans are not yet disclosed.
Brentuximab vedotin → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Takeda's continued investment in brentuximab vedotin through active clinical trials (NCT01909934, NCT05673785) and recent milestone activity (September 2025) suggests commitment to deepening the clinical evidence base and potentially expanding the indication or patient population. The recent European Union approval (February 2026) represents significant regulatory progress in a major market, enhancing commercial opportunity. Multiple PBS code listings in Australia across 2014-2019 indicate potential label expansions or formulation variations, suggesting active clinical development beyond initial approval.
Competitive Implications: The lymphoma treatment market remains highly competitive with diverse mechanistic approaches. Brentuximab vedotin's sustained multi-market regulatory presence and active trial engagement position it as an established competitor. However, the emergence of novel targeted therapies and immunotherapies may create pressure for continued clinical evidence generation to maintain market share. The specific mechanisms of action and targets for competing agents remain partially undisclosed, limiting detailed competitive positioning analysis.
Future Catalysts: Potential catalysts include results from ongoing trials NCT01909934 and NCT05673785, which may support label expansions, new indication approvals, or combination therapy strategies. Additional regulatory approvals in emerging markets (particularly China/NMPA) could expand commercial opportunity. Patent expiration timeline remains undisclosed, representing a significant future inflection point for the program.
Expected Milestones: Next expected milestone timing and nature not yet disclosed. Continued monitoring of trial completion dates and regulatory submissions in major markets recommended.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.